{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:14:58Z","timestamp":1789704898805,"version":"4.0.1"},"reference-count":211,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1053\/j.semdp.2021.10.006","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T12:19:52Z","timestamp":1635941992000},"page":"58-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors"],"prefix":"10.1053","volume":"39","author":[{"given":"Natalia","family":"Buza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semdp.2021.10.006_bib0001","series-title":"International Agency for Research on Cancer","year":"2020"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2018.10.015","article-title":"The prognostic value of p16 and p53 expression for survival after vulvar cancer: a systematic review and meta-analysis","volume":"152","author":"Sand","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0003","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ijc.31139","article-title":"Does HPV status influence survival after vulvar cancer?","volume":"142","author":"Rasmussen","year":"2018","journal-title":"Int J Cancer"},{"issue":"22","key":"10.1053\/j.semdp.2021.10.006_bib0004","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1158\/1078-0432.CCR-17-1302","article-title":"Genomic characterization of vulvar (Pre)cancers identifies distinct molecular subtypes with prognostic significance","volume":"23","author":"Nooij","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/modpathol.2016.187","article-title":"Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA","volume":"30","author":"Watkins","year":"2017","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0006","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41379-020-00651-3","article-title":"Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome","volume":"34","author":"Tessier-Cloutier","year":"2021","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0007","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/00000478-200405000-00012","article-title":"Vulvar acanthosis with altered differentiation: a precursor to verrucous carcinoma?","volume":"28","author":"Nascimento","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0008","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.semdp.2020.09.006","article-title":"Putative precancerous lesions of vulvar squamous cell carcinoma","volume":"38","author":"Jenkins","year":"2021","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0009","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/modpathol.2010.192","article-title":"Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma","volume":"24","author":"van de Nieuwenhof","year":"2011","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00000478-200003000-00013","article-title":"Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathologic study including analysis of HPV and p53 expression","volume":"24","author":"Yang","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1053\/j.semdp.2021.10.006_bib0011","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cam4.1961","article-title":"Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention","volume":"8","author":"Dovey de la Cour","year":"2019","journal-title":"Cancer Med"},{"key":"10.1053\/j.semdp.2021.10.006_bib0013","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/269468","article-title":"Prevalence and distribution of high-risk genotypes of HPV in women with severe cervical lesions in Madrid, Spain: importance of detecting genotype 16 and other high-risk genotypes","author":"Mateos Lindemann","year":"2011","journal-title":"Adv Prev Med"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0014","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/PAS.0000000000000986","article-title":"International endocervical adenocarcinoma criteria and classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix","volume":"42","author":"Stolnicu","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jclinpath-2018-205632","article-title":"International endocervical adenocarcinoma criteria and Classification (IECC): correlation with adverse clinicopathological features and patient outcome","volume":"72","author":"Hodgson","year":"2019","journal-title":"J Clin Pathol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0016","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41379-019-0305-x","article-title":"Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing","volume":"32","author":"Garg","year":"2019","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0017","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/CS20050369","article-title":"Molecular biology of human papillomavirus infection and cervical cancer","volume":"110","author":"Doorbar","year":"2006","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0018","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ctrv.2008.10.005","article-title":"p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis","volume":"35","author":"Tsoumpou","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0019","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.MP.0000077518.78046.0C","article-title":"p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types","volume":"16","author":"Agoff","year":"2003","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/modpathol.2015.126","article-title":"p16 staining has limited value in predicting the outcome of histological low-grade squamous intraepithelial lesions of the cervix","volume":"29","author":"Sagasta","year":"2016","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1053\/j.semdp.2021.10.006_bib0021","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.5858\/arpa.2016-0541-RA","article-title":"Immunohistochemistry in gynecologic pathology: an example-based practical update","volume":"141","author":"Buza","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0022","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PGP.0b013e31826916c7","article-title":"The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the college of American pathologists and the American society for colposcopy and cervical pathology","volume":"32","author":"Darragh","year":"2013","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0023","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1309\/AJCPXSVCDZ3D5MZM","article-title":"Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia","volume":"133","author":"Bergeron","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0024","first-page":"284a","article-title":"The impact of P16 immunostain on the diagnostic agreement of cervical biopsies using the new WHO terminology","volume":"28","author":"Fernandez","year":"2015","journal-title":"Modern Pathol"},{"issue":"11","key":"10.1053\/j.semdp.2021.10.006_bib0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00000478-200211000-00001","article-title":"p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia","volume":"26","author":"Klaes","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1053\/j.semdp.2021.10.006_bib0026","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/cup.12525","article-title":"Grading of atypia in genital skin lesions: routine microscopic evaluation and use of p16 immunostaining","volume":"42","author":"Ezaldein","year":"2015","journal-title":"J Cutan Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0027","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ijc.32078","article-title":"Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina","volume":"145","author":"Bertoli","year":"2019","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0028","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/bjc.2014.32","article-title":"Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina","volume":"110","author":"Hellman","year":"2014","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1053\/j.semdp.2021.10.006_bib0029","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.ejca.2014.07.018","article-title":"Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples","volume":"50","author":"Alemany","year":"2014","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1053\/j.semdp.2021.10.006_bib0030","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/PAS.0b013e3181b40081","article-title":"HPV-negative vulvar intraepithelial neoplasia (VIN) with basaloid histologic pattern: an unrecognized variant of simplex (differentiated) VIN","volume":"33","author":"Ordi","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0031","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/PAS.0000000000000291","article-title":"Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss","volume":"39","author":"Singh","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0032","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1523-1747.2002.19513.x","article-title":"Overexpression of wild-type p53 in lichen sclerosus adjacent to human papillomavirus-negative vulvar cancer","volume":"119","author":"Vanin","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0033","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2559.2005.02321.x","article-title":"p53 immunostaining in lichen sclerosus is related to ischaemic stress and is not a marker of differentiated vulvar intraepithelial neoplasia (d-VIN)","volume":"48","author":"Liegl","year":"2006","journal-title":"Histopathology"},{"issue":"11","key":"10.1053\/j.semdp.2021.10.006_bib0034","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1097\/PAS.0000000000001540","article-title":"HPV-independent precursors mimicking high-grade squamous intraepithelial lesions (HSIL) of the vulva","volume":"44","author":"Rakislova","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0035","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41379-018-0021-y","article-title":"Differential expression patterns of GATA3 in usual and differentiated types of vulvar intraepithelial neoplasia: potential diagnostic implications","volume":"31","author":"Goyal","year":"2018","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0036","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/PGP.0000000000000317","article-title":"Assessment of CK17 as a marker for the diagnosis of differentiated vulvar intraepithelial neoplasia","volume":"36","author":"Podoll","year":"2017","journal-title":"Int J Gynecol Pathol"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0037","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00428-018-2436-8","article-title":"Differentiated vulvar intraepithelial neoplasia (dVIN): the most helpful histological features and the utility of cytokeratins 13 and 17","volume":"473","author":"Dasgupta","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1053\/j.semdp.2021.10.006_bib0038","doi-asserted-by":"crossref","DOI":"10.1111\/his.14109","article-title":"Performance of the pattern based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma","author":"Kortekaas","year":"2020","journal-title":"Histopathology"},{"key":"10.1053\/j.semdp.2021.10.006_bib0039","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-020-0524-1","article-title":"Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status","author":"Tessier-Cloutier","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-020-0527-y","article-title":"p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns","author":"Thompson","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0041","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/PGP.0000000000000751","article-title":"Tumor typing of endocervical adenocarcinoma: contemporary review and recommendations from the international society of gynecological pathologists","volume":"40","author":"Stolnicu","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0042","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/00000478-199804000-00007","article-title":"Apoptotic bodies: a consistent morphologic feature of endocervical adenocarcinoma in situ","volume":"22","author":"Biscotti","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"22","key":"10.1053\/j.semdp.2021.10.006_bib0043","doi-asserted-by":"crossref","first-page":"12754","DOI":"10.1073\/pnas.96.22.12754","article-title":"In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis","volume":"96","author":"Nuovo","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"10.1053\/j.semdp.2021.10.006_bib0044","article-title":"A detailed immunohistochemical analysis of a large series of cervical and vaginal gastric-type adenocarcinomas","author":"Carleton","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/PAS.0b013e31821534b9","article-title":"Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus","volume":"35","author":"Park","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0046","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2559.2010.03632.x","article-title":"p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection","volume":"57","author":"Houghton","year":"2010","journal-title":"Histopathology"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0047","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/IGC.0b013e3182981bdc","article-title":"Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma","volume":"23","author":"Ueno","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0048","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","article-title":"High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations","volume":"38","author":"Murali","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"10","key":"10.1053\/j.semdp.2021.10.006_bib0049","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1097\/PAS.0b013e3181ac35f5","article-title":"Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases","volume":"33","author":"Yemelyanova","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0050","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/01.pgp.0000235065.31301.3e","article-title":"Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma","volume":"26","author":"Chiesa-Vottero","year":"2007","journal-title":"Int J Gynecol Pathol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0051","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/PAS.0b013e3181758831","article-title":"Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms","volume":"32","author":"Ronnett","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0052","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/01.pas.0000213369.71676.25","article-title":"p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas","volume":"31","author":"Vang","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0053","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/PAS.0000000000000800","article-title":"HR-HPV E6\/E7 mRNA in situ hybridization: validation against PCR, DNA in situ Hybridization, and p16 immunohistochemistry in 102 samples of cervical, vulvar, anal, and head and neck neoplasia","volume":"41","author":"Mills","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0054","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2559.2002.01465.x","article-title":"Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia","volume":"41","author":"Cameron","year":"2002","journal-title":"Histopathology"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00000478-200302000-00006","article-title":"p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations","volume":"27","author":"Negri","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0056","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/PGP.0b013e3181877a73","article-title":"P16 immunostaining patterns in microglandular hyperplasia of the cervix and their significance","volume":"28","author":"Roh","year":"2009","journal-title":"Int J Gynecol Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0057","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/PGP.0000000000000086","article-title":"Mitotically active microglandular hyperplasia of the cervix: a case series with implications for the differential diagnosis","volume":"33","author":"Abi-Raad","year":"2014","journal-title":"Int J Gynecol Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0058","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/01.pas.0000213434.91868.b0","article-title":"Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix","volume":"31","author":"Kojima","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0059","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/his.13887","article-title":"Immunohistochemical expression of HIK1083 and MUC6 in endometrial carcinomas","volume":"75","author":"Hodgson","year":"2019","journal-title":"Histopathology"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13000-019-0852-y","article-title":"Primary endocervical gastric-type adenocarcinoma: a clinicopathologic and immunohistochemical analysis of 23 cases","volume":"14","author":"Lu","year":"2019","journal-title":"Diagn Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0061","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/PGP.0000000000000309","article-title":"Comprehensive Analysis of PAX8 expression in epithelial malignancies of the uterine cervix","volume":"36","author":"Wong","year":"2017","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0062","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00428-018-2469-z","article-title":"Trefoil factor family 2 protein: a potential immunohistochemical marker for aiding diagnosis of lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix","volume":"474","author":"Asaka","year":"2019","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0063","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/PGP.0000000000000680","article-title":"Trefoil factor 2 (TFF2) as a surrogate marker for endocervical gastric-type carcinoma","volume":"40","author":"Takako","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0064","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/PGP.0000000000000102","article-title":"Differential patterns of PAX8, p16, and ER immunostains in mesonephric lesions and adenocarcinomas of the cervix","volume":"33","author":"Goyal","year":"2014","journal-title":"Int J Gynecol Pathol"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0065","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/PAS.0b013e31824a72c6","article-title":"Mesonephric adenocarcinomas of the uterine cervix and corpus: hPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-beta","volume":"36","author":"Kenny","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0066","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1097\/PAS.0000000000001142","article-title":"A Comparison of GATA3, TTF1, CD10, and calretinin in identifying mesonephric and mesonephric-like carcinomas of the gynecologic tract","volume":"42","author":"Pors","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1053\/j.semdp.2021.10.006_bib0067","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/PAS.0000000000000471","article-title":"GATA3 is a sensitive and specific marker of benign and malignant mesonephric lesions in the lower female genital tract","volume":"39","author":"Howitt","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0068","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/PGP.0000000000000167","article-title":"Differential expression patterns of GATA3 in uterine mesonephric and nonmesonephric lesions","volume":"34","author":"Roma","year":"2015","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0069","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/00313020601123961","article-title":"Immunohistochemistry as a diagnostic aid in cervical pathology","volume":"39","author":"McCluggage","year":"2007","journal-title":"Pathology"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004347-200201000-00003","article-title":"A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas","volume":"21","author":"McCluggage","year":"2002","journal-title":"Int J Gynecol Pathol"},{"issue":"8","key":"10.1053\/j.semdp.2021.10.006_bib0071","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/00000478-200208000-00004","article-title":"Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas","volume":"26","author":"Staebler","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0072","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/PGP.0000000000000553","article-title":"Guidelines to aid in the distinction of endometrial and endocervical carcinomas, and the distinction of independent primary carcinomas of the endometrium and adnexa from metastatic spread between these and other sites","volume":"38","author":"Stewart","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"7447","key":"10.1053\/j.semdp.2021.10.006_bib0073","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0074","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2016.07.090","article-title":"Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment","volume":"143","author":"Talhouk","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0075","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0076","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0077","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/PGP.0000000000000512","article-title":"Issues in the differential diagnosis of uterine low-grade endometrioid carcinoma,including mixed endometrial carcinomas: recommendations from the international society of gynecological pathologists","volume":"38","author":"Rabban","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0078","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"Kobel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0079","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0080","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2559.2011.03907.x","article-title":"Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance","volume":"59","author":"McCluggage","year":"2011","journal-title":"Histopathology"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0081","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/PGP.0000000000000243","article-title":"TP53 mutational spectrum in endometrioid and serous endometrial cancers","volume":"35","author":"Schultheis","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0082","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000001713","article-title":"Cytoplasmic pattern p53 immunoexpression in pelvic and endometrial carcinomas with TP53 mutation involving nuclear localization domains: an uncommon but potential diagnostic pitfall with clinical implications","author":"Rabban","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0083","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0084","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-4436","article-title":"Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas","author":"Momeni-Boroujeni","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0085","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0086","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2013.102","article-title":"Reproducibility of histological cell type in high-grade endometrial carcinoma","volume":"26","author":"Han","year":"2013","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1053\/j.semdp.2021.10.006_bib0087","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/PAS.0b013e31828c63ed","article-title":"Histotype-genotype correlation in 36 high-grade endometrial carcinomas","volume":"37","author":"Hoang","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0088","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PAS.0000000000001598","article-title":"Molecularly classified uterine FIGO grade 3 endometrioid carcinomas show distinctive clinical outcomes but overlapping morphologic features","volume":"45","author":"Joehlin-Price","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0089","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas","volume":"250","author":"Leon-Castillo","year":"2020","journal-title":"J Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/modpathol.2013.144","article-title":"ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas","volume":"27","author":"Allo","year":"2014","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1053\/j.semdp.2021.10.006_bib0091","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/modpathol.3800620","article-title":"Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis","volume":"19","author":"Reid-Nicholson","year":"2006","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0092","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PGP.0000000000000583","article-title":"Clinicopathologic and immunohistochemical correlates of CTNNB1 mutated endometrial endometrioid carcinoma","volume":"39","author":"Costigan","year":"2020","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0093","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PGP.0000000000000162","article-title":"Endometrial carcinomas with clear cells: a study of a heterogeneous group of tumors including interobserver variability, mutation analysis, and immunohistochemistry with HNF-1beta","volume":"34","author":"Han","year":"2015","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0094","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/PAS.0000000000000085","article-title":"Frequent expression of napsin a in clear cell carcinoma of the endometrium: potential diagnostic utility","volume":"38","author":"Fadare","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/his.12286","article-title":"Immunohistochemical characterization of prototypical endometrial clear cell carcinoma\u2013diagnostic utility of HNF-1beta and oestrogen receptor","volume":"64","author":"Hoang","year":"2014","journal-title":"Histopathology"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0096","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.humpath.2015.03.008","article-title":"Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium","volume":"46","author":"Iwamoto","year":"2015","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1053\/j.semdp.2021.10.006_bib0097","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/PAS.0000000000000436","article-title":"Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma","volume":"39","author":"Lim","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0098","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1016\/j.humpath.2013.07.033","article-title":"Utility of alpha-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas","volume":"44","author":"Fadare","year":"2013","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1053\/j.semdp.2021.10.006_bib0099","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.2013.35","article-title":"The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium","volume":"26","author":"Fadare","year":"2013","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0101","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/PAS.0000000000001209","article-title":"Targeted molecular and immunohistochemical analyses of endometrial clear cell carcinoma show that POLE mutations and DNA mismatch repair protein deficiencies are uncommon","volume":"43","author":"Baniak","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0102","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/his.12581","article-title":"Targeted mutation analysis of endometrial clear cell carcinoma","volume":"66","author":"Hoang","year":"2015","journal-title":"Histopathology"},{"key":"10.1053\/j.semdp.2021.10.006_bib0103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.humpath.2019.06.005","article-title":"Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases","volume":"92","author":"Zannoni","year":"2019","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0104","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.humpath.2006.12.018","article-title":"Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium","volume":"38","author":"Yamamoto","year":"2007","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/PAI.0b013e31824973d1","article-title":"Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma","volume":"20","author":"Fadare","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"8","key":"10.1053\/j.semdp.2021.10.006_bib0106","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/PAI.0000000000000232","article-title":"Clinicopathologic and immunohistochemical characterization of dedifferentiated endometrioid adenocarcinoma","volume":"24","author":"Li","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0107","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/modpathol.2010.41","article-title":"Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms","volume":"23","author":"Tafe","year":"2010","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0108","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/PGP.0000000000000248","article-title":"Undifferentiated carcinoma of the endometrium: an expanded immunohistochemical analysis including PAX-8 and basal-like carcinoma surrogate markers","volume":"35","author":"Ramalingam","year":"2016","journal-title":"Int J Gynecol Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0109","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/PAT.0000000000000270","article-title":"SWI\/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma","volume":"47","author":"Stewart","year":"2015","journal-title":"Pathology"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PAS.0000000000000941","article-title":"Undifferentiated endometrial carcinomas show frequent loss of core switch\/sucrose nonfermentable complex proteins","volume":"42","author":"Kobel","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0111","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2016.156","article-title":"Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas","volume":"29","author":"Coatham","year":"2016","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0112","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/modpathol.2015.155","article-title":"Loss of switch\/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas","volume":"29","author":"Karnezis","year":"2016","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0113","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/PAS.0000000000001401","article-title":"Mesonephric-like carcinoma of the endometrium: a subset of endometrial carcinoma with an aggressive behavior","volume":"44","author":"Euscher","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0114","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/PAS.0000000000001193","article-title":"A combined morphologic and molecular approach to retrospectively identify KRAS-mutated mesonephric-like adenocarcinomas of the endometrium","volume":"43","author":"Kolin","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0115","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/his.12895","article-title":"Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas","volume":"68","author":"McFarland","year":"2016","journal-title":"Histopathology"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0116","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/PAS.0000000000001381","article-title":"Endometrial gastric (Gastrointestinal)-type mucinous lesions: report of a series illustrating the spectrum of benign and malignant lesions","volume":"44","author":"Wong","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0117","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/PAS.0000000000001474","article-title":"Endometrial gastric-type carcinoma: an aggressive and morphologically heterogenous new histotype arising from gastric metaplasia of the endometrium","volume":"44","author":"Travaglino","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0118","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1066896917743010","article-title":"Gastric-type endometrial adenocarcinoma: report of two cases in patients from the United States","volume":"26","author":"McCarthy","year":"2018","journal-title":"Int J Surg Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0119","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1746-1596-8-128","article-title":"Endometrioid adenocarcinoma with simultaneous endocervical and intestinal-type mucinous differentiation: report of a rare phenomenon and the immunohistochemical profile","volume":"8","author":"Buell-Gutbrod","year":"2013","journal-title":"Diagn Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0120","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/PGP.0000000000000227","article-title":"Pseudomyxoma-type invasion in gastrointestinal adenocarcinomas of endometrium and cervix: a report of 2 cases","volume":"35","author":"Rubio","year":"2016","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0121","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/PAI.0b013e318174f012","article-title":"Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation","volume":"17","author":"Park","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0122","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/PGP.0000000000000544","article-title":"SATB2 is consistently expressed in squamous morules associated with endometrioid proliferative lesions and in the stroma of atypical polypoid adenomyoma","volume":"38","author":"McCluggage","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0123","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/path.2744","article-title":"The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas","volume":"222","author":"Kobel","year":"2010","journal-title":"J Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0124","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cjp2.53","article-title":"Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma","volume":"2","author":"Kobel","year":"2016","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/PGP.0000000000000725","article-title":"The many uses of p53 immunohistochemistry in gynecological pathology: proceedings of the ISGyP companion society session at the 2020 USCAP annual9 meeting","volume":"40","author":"Kobel","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0126","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/PGP.0000000000000530","article-title":"Ovarian carcinoma histotype: strengths and limitations of integrating morphology with immunohistochemical predictions","volume":"38","author":"Kobel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0127","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/PGP.0000000000000274","article-title":"An Immunohistochemical algorithm for ovarian carcinoma typing","volume":"35","author":"Kobel","year":"2016","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0129","article-title":"WT1 positive ovarian endometrioid tumors: observations from consult cases and strategies for distinguishing from serous neoplasms","author":"Rajendran","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0b013e3181788546","article-title":"A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary","volume":"33","author":"Kobel","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.humpath.2018.04.025","article-title":"Role of HNF1beta in the differential diagnosis of yolk sac tumor from other germ cell tumors","volume":"81","author":"Rougemont","year":"2018","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0132","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/PGP.0000000000000466","article-title":"Clear cell renal cell carcinoma metastatic to the gynecologic tract: a clinicopathologic analysis of 17 cases","volume":"37","author":"Fadare","year":"2018","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0133","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41379-020-0618-9","article-title":"Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses","volume":"34","author":"Kang","year":"2021","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0134","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1038\/s41467-019-11862-x","article-title":"The molecular origin and taxonomy of mucinous ovarian carcinoma","volume":"10","author":"Cheasley","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0135","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/his.13177","article-title":"Clinical, morphological and immunohistochemical evidence that small-cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ-cell neoplasm","volume":"70","author":"McCluggage","year":"2017","journal-title":"Histopathology"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0136","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/modpathol.2017.81","article-title":"Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups","volume":"30","author":"Parra-Herran","year":"2017","journal-title":"Mod Pathol"},{"issue":"20","key":"10.1053\/j.semdp.2021.10.006_bib0137","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1158\/1078-0432.CCR-20-1268","article-title":"Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma","volume":"26","author":"Kramer","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0138","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5858\/arpa.2018-0289-RA","article-title":"Frozen section diagnosis of ovarian epithelial tumors: diagnostic pearls and pitfalls","volume":"143","author":"Buza","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0139","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/PAS.0b013e318216c112","article-title":"A comprehensive analysis of PAX8 expression in human epithelial tumors","volume":"35","author":"Laury","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0140","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3182299c25","article-title":"Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases","volume":"35","author":"Chu","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0141","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41379-019-0302-0","article-title":"A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases","volume":"32","author":"Meagher","year":"2019","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0142","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/his.13772","article-title":"Nuclear beta-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome","volume":"74","author":"Wang","year":"2019","journal-title":"Histopathology"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0143","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/his.13894","article-title":"Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas","volume":"75","author":"Ritterhouse","year":"2019","journal-title":"Histopathology"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0144","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.path.2016.01.004","article-title":"Lynch syndrome: female genital tract cancer diagnosis and screening","volume":"9","author":"Mills","year":"2016","journal-title":"Surg Pathol Clin"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0145","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/PAS.0000000000000602","article-title":"Mismatch repair protein expression in clear cell carcinoma of the ovary: incidence and morphologic associations in 109 cases","volume":"40","author":"Bennett","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0146","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/14737159.2016.1156533","article-title":"Mismatch repair deficiency testing in clinical practice","volume":"16","author":"Buza","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0147","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.cell.2010.05.002","article-title":"SnapShot: DNA mismatch repair","volume":"141","author":"Larrea","year":"2010","journal-title":"Cell"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0148","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2353\/jmoldx.2008.080031","article-title":"Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. the utility of immunohistochemistry","volume":"10","author":"Shia","year":"2008","journal-title":"J Mol Diagn"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0149","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00428-004-1090-5","article-title":"The utility of immunohistochemical detection of DNA mismatch repair gene proteins","volume":"445","author":"Shia","year":"2004","journal-title":"Virchows Arch"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0150","first-page":"3485","article-title":"Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families","volume":"62","author":"Wahlberg","year":"2002","journal-title":"Cancer Res"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0151","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/PAS.0000000000000663","article-title":"Unusual mismatch repair immunohistochemical patterns in endometrial carcinoma","volume":"40","author":"Watkins","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1053\/j.semdp.2021.10.006_bib0152","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.humpath.2010.11.016","article-title":"Challenging cases encountered in colorectal cancer screening for Lynch syndrome reveal novel findings: nucleolar MSH6 staining and impact of prior chemoradiation therapy","volume":"42","author":"Radu","year":"2011","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0153","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1066896919878830","article-title":"Pure discrete punctate nuclear staining pattern for MLH1 protein does not represent intact nuclear expression","volume":"28","author":"Zhang","year":"2020","journal-title":"Int J Surg Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0154","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/PAS.0000000000000620","article-title":"A practical approach to the evaluation of gastrointestinal tract carcinomas for lynch syndrome","volume":"40","author":"Pai","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0155","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/PAS.0000000000000415","article-title":"Abrupt loss of MLH1 and PMS2 expression in endometrial carcinoma: molecular and morphologic analysis of 6 cases","volume":"39","author":"Pai","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"17","key":"10.1053\/j.semdp.2021.10.006_bib0156","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1158\/1078-0432.CCR-16-2994","article-title":"Can microsatellite status of colorectal cancer be reliably assessed after neoadjuvant therapy?","volume":"23","author":"Goldstein","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1053\/j.semdp.2021.10.006_bib0157","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1158\/0008-5472.CAN-06-1114","article-title":"Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients","volume":"66","author":"Hampel","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.semdp.2021.10.006_bib0158","doi-asserted-by":"crossref","DOI":"10.1586\/14737159.2016.1156533","article-title":"Mismatch repair deficiency testing in clinical practice","author":"Buza","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"issue":"4","key":"10.1053\/j.semdp.2021.10.006_bib0159","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/jnci\/djs525","article-title":"Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome","volume":"105","author":"Win","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0160","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/his.12934","article-title":"Significant frequency of MSH2\/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas","volume":"69","author":"Rambau","year":"2016","journal-title":"Histopathology"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0161","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2014.07.100","article-title":"Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary","volume":"135","author":"Vierkoetter","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0162","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/cam4.3688","article-title":"Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer","volume":"10","author":"Hodan","year":"2021","journal-title":"Cancer Med"},{"issue":"11","key":"10.1053\/j.semdp.2021.10.006_bib0163","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/PAS.0000000000000321","article-title":"Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer","volume":"38","author":"Mills","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0164","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2013.04.022","article-title":"Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center","volume":"130","author":"Moline","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-020-0455-x","article-title":"Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients","author":"Wong","year":"2020","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1053\/j.semdp.2021.10.006_bib0166","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41379-018-0044-4","article-title":"Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from lynch syndrome surveillance","volume":"31","author":"Niskakoski","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0167","doi-asserted-by":"crossref","DOI":"10.1111\/his.14386","article-title":"DNA mismatch repair deficient non-neoplastic endometrial glands are common in lynch syndrome patients and are present at a higher density compared to the colon","author":"Hegazy","year":"2021","journal-title":"Histopathology"},{"key":"10.1053\/j.semdp.2021.10.006_bib0168","article-title":"Mismatch repair protein expression in endometrioid intraepithelial neoplasia\/atypical hyperplasia: should we screen for lynch syndrome in precancerous lesions?","author":"Lucas","year":"2018","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0169","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2015.01.541","article-title":"Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas","volume":"137","author":"McConechy","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1053\/j.semdp.2021.10.006_bib0170","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/1940-6207.CAPR-11-0288","article-title":"Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing","volume":"5","author":"Bartley","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0171","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41379-018-0179-3","article-title":"Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation","volume":"32","author":"Wu","year":"2019","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0172","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH701>3.0.CO;2-2","article-title":"Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients","volume":"192","author":"de Leeuw","year":"2000","journal-title":"J Pathol"},{"issue":"8","key":"10.1053\/j.semdp.2021.10.006_bib0173","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/gcc.20678","article-title":"Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome","volume":"48","author":"Niessen","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0174","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen","year":"2020","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0175","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ygyno.2017.07.003","article-title":"Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival","volume":"146","author":"Cosgrove","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"6712","key":"10.1053\/j.semdp.2021.10.006_bib0176","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/25292","article-title":"Genetic instabilities in human cancers","volume":"396","author":"Lengauer","year":"1998","journal-title":"Nature"},{"issue":"26","key":"10.1053\/j.semdp.2021.10.006_bib0177","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.semdp.2021.10.006_bib0178","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"6349","key":"10.1053\/j.semdp.2021.10.006_bib0179","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1053\/j.semdp.2021.10.006_bib0181","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semdp.2021.10.006_bib0182","first-page":"1","article-title":"A review of immune checkpoint blockade therapy in endometrial cancer","volume":"40","author":"Green","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"20","key":"10.1053\/j.semdp.2021.10.006_bib0183","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0184","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semdp.2021.10.006_bib0185","unstructured":"National Comprehensive Cancer Network. Uterine Neoplasms (Version 4.2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf. Accessed October 6, 2019."},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0186","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ygyno.2020.12.021","article-title":"Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations","volume":"160","author":"Hamilton","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0187","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1053\/j.semdp.2021.10.006_bib0188","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0189","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/his.14001","article-title":"Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study","volume":"76","author":"Cuevas","year":"2020","journal-title":"Histopathology"},{"issue":"5","key":"10.1053\/j.semdp.2021.10.006_bib0190","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/PAS.0000000000001682","article-title":"HER-2 Amplification in Uterine serous carcinoma and serous endometrial intraepithelial carcinoma","volume":"45","author":"Banet","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0191","article-title":"HER2 testing in endometrial serous carcinoma","author":"Buza","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0192","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0193","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-021-00746-5","article-title":"Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study","author":"Buza","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0194","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma? discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity","author":"Rottmann","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0195","article-title":"HER2 expression in endometrial cancers diagnosed as clear cell carcinoma","author":"Cagaanan","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0196","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semdp.2021.10.006_bib0197","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-021-03017-5","article-title":"Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy","author":"Yoshida","year":"2021","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0198","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010044","article-title":"HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0199","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00795-018-0202-2","article-title":"Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification","volume":"52","author":"Nakamura","year":"2019","journal-title":"Med Mol Morphol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0200","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1097\/PGP.0000000000000755","article-title":"The role of predictive biomarkers in endocervical adenocarcinoma: recommendations from the international society of gynecological pathologists","volume":"40","author":"Bosse","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0201","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cjp2.184","article-title":"An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the international endocervical adenocarcinoma criteria and classification","volume":"7","author":"Shi","year":"2021","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GCO.0000000000000603","article-title":"Optimizing immunotherapy for gynecologic cancers","volume":"32","author":"Rubinstein","year":"2020","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"7","key":"10.1053\/j.semdp.2021.10.006_bib0203","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3776","article-title":"Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma","volume":"4","author":"Lheureux","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1053\/j.semdp.2021.10.006_bib0204","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2217\/imt-2016-0119","article-title":"Pembrolizumab in recurrent advanced cervical squamous carcinoma","volume":"9","author":"Martinez","year":"2017","journal-title":"Immunotherapy"},{"issue":"17","key":"10.1053\/j.semdp.2021.10.006_bib0205","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0206","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2019.12.034","article-title":"Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528\/NRG-GY002)","volume":"157","author":"Santin","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"36","key":"10.1053\/j.semdp.2021.10.006_bib0207","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.semdp.2021.10.006_bib0208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PGP.0000000000000701","article-title":"PD-L1 interpretation in cervical carcinomas: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting","volume":"40","author":"Mills","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"9","key":"10.1053\/j.semdp.2021.10.006_bib0209","first-page":"5087","article-title":"Identifying rational candidates for immunotherapy targeting PD-1\/PD-L1 in cervical cancer","volume":"37","author":"Kim","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semdp.2021.10.006_bib0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-019-0433-3","article-title":"Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia","author":"Curley","year":"2020","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2021.10.006_bib0211","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PAS.0000000000000783","article-title":"PD-L1 expression in mismatch repair-deficient endometrial carcinomas, including lynch syndrome-associated and MLH1 promoter hypermethylated tumors","volume":"41","author":"Sloan","year":"2017","journal-title":"Am J Surg Pathol"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257021000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257021000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:23:19Z","timestamp":1760037799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257021000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":211,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0740257021000800"],"URL":"https:\/\/doi.org\/10.1053\/j.semdp.2021.10.006","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semdp.2021.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}